Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Upgraded by Wall Street Zen to “Buy” Rating

Wall Street Zen upgraded shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) from a hold rating to a buy rating in a report published on Saturday.

Separately, Hsbc Global Res upgraded shares of Bayer Aktiengesellschaft to a “hold” rating in a report on Monday, April 28th.

Bayer Aktiengesellschaft Stock Performance

BAYRY opened at $7.24 on Friday. The company has a current ratio of 1.32, a quick ratio of 0.81 and a debt-to-equity ratio of 1.19. The firm has a market capitalization of $28.45 billion, a PE ratio of -27.85 and a beta of 0.84. The firm’s 50-day moving average price is $6.35 and its 200 day moving average price is $5.81. Bayer Aktiengesellschaft has a twelve month low of $4.79 and a twelve month high of $8.58.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last posted its earnings results on Tuesday, May 13th. The company reported $0.65 earnings per share for the quarter, beating the consensus estimate of $0.63 by $0.02. The company had revenue of $15.27 billion for the quarter, compared to analyst estimates of $13.39 billion. Bayer Aktiengesellschaft had a negative net margin of 2.02% and a positive return on equity of 16.90%. As a group, sell-side analysts expect that Bayer Aktiengesellschaft will post 1.31 EPS for the current fiscal year.

Bayer Aktiengesellschaft Increases Dividend

The business also recently declared a dividend, which was paid on Monday, May 12th. Stockholders of record on Wednesday, April 30th were paid a $0.0224 dividend. This represents a dividend yield of 0.38%. This is an increase from Bayer Aktiengesellschaft’s previous dividend of $0.02. The ex-dividend date was Tuesday, April 29th. Bayer Aktiengesellschaft’s payout ratio is -2.17%.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.